XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 03, 2024
shares
Feb. 29, 2024
USD ($)
Jan. 26, 2024
USD ($)
shares
Oct. 06, 2022
USD ($)
Oct. 03, 2022
Mar. 31, 2021
USD ($)
Apr. 28, 2019
USD ($)
Jan. 04, 2018
USD ($)
shares
Feb. 29, 2024
USD ($)
Jun. 30, 2012
Jun. 30, 2024
USD ($)
shares
Mar. 31, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Jun. 30, 2024
ILS (₪)
Feb. 29, 2024
ILS (₪)
Dec. 11, 2022
USD ($)
Dec. 11, 2022
ILS (₪)
Jun. 10, 2021
USD ($)
Loss Contingencies [Line Items]                                        
Net sales royalty percenatge                           3.00%            
Gross proceeds from cash fee percentage         7.00%                              
Gross proceeds from management fee percentage         1.00%                              
Stock issued during period, value, new issues                     $ 2,022 [1] $ 2,397 [2] $ 6,558              
Litigation settlement amount     $ 2,154                                  
Settlement agreement liability                             $ 2,211          
Insurance recoverable                             1,335          
Settlement amount recovery                             1,100          
Legal expense                             235          
Non operating loss on legal settlement                             $ 1,111          
Joseph Mona [Member]                                        
Loss Contingencies [Line Items]                                        
Purchase price of plaintiffs           $ 485                            
Chief Executive Officer [Member]                                        
Loss Contingencies [Line Items]                                        
Contigent bonus   $ 298             $ 298                      
Contigent description                 The first 50% of the CEO’s contingent bonus ($149) is payable upon the Company raising at least $3,000 in new funds by June 30, 2024. The remaining 50% ($149), payable upon the Company raising at least $6,000 in new funds by September 30, 2024 (cumulative, so if $3,000 is not raised by June 30, 2024 but the full $6,000 is raised by September 30, 2024, the full amount is payable).                      
Other Executives [Member]                                        
Loss Contingencies [Line Items]                                        
Contigent bonus   $ 61             $ 61               ₪ 230,736      
Contigent description   which is payable upon the Company raising at least $3,000 in new funds by September 30, 2024.                                    
Common Stock [Member]                                        
Loss Contingencies [Line Items]                                        
Stock issued during period, value, new issues                     $ 16 [1] $ 17 [2] $ 35              
Number of share issued | shares                     1,566,669 [1] 1,685,682 [2] 3,576,689 [2]              
Device [Member]                                        
Loss Contingencies [Line Items]                                        
Royalties percentage       3.00%                                
Integrated Product [Member]                                        
Loss Contingencies [Line Items]                                        
Royalties percentage       1.50%                                
Securities Purchase Agreement [Member]                                        
Loss Contingencies [Line Items]                                        
Purchase price of plaintiffs                           $ 6,750            
Securities Purchase Agreement [Member] | Common Stock [Member]                                        
Loss Contingencies [Line Items]                                        
Number of share issued | shares 1,566,669                                      
Litigation Settlement [Member]                                        
Loss Contingencies [Line Items]                                        
Payment for litigation settlement     $ 1,100                 $ 1,100                
Restricted common shares issued for legal settlement | shares     1,005,965                                  
Insurance recovery amount                       $ 1,335                
Litigation Settlement [Member] | Common Stock [Member]                                        
Loss Contingencies [Line Items]                                        
Number of share issued | shares                       1,005,965   1,005,965            
Israeli Innovation Authority [Member]                                        
Loss Contingencies [Line Items]                                        
Grants receivable                       $ 74           $ 83 ₪ 300,000  
Additional grant receivable                     $ 447     $ 447   ₪ 1,620,000        
Israeli Innovation Authority [Member] | Minimum [Member]                                        
Loss Contingencies [Line Items]                                        
Net sales royalty percenatge                           3.00%            
Israeli Innovation Authority [Member] | Maximum [Member]                                        
Loss Contingencies [Line Items]                                        
Net sales royalty percenatge                           5.00%            
Israeli Innovation Authority [Member] | CardioSert Ltd [Member]                                        
Loss Contingencies [Line Items]                                        
Repayment of government grants               $ 530                        
Israeli Innovation Authority [Member] | Nitiloop [Member]                                        
Loss Contingencies [Line Items]                                        
Repayment of government grants       $ 925                                
Ministry of Economy [Member]                                        
Loss Contingencies [Line Items]                                        
Grants receivable                     $ 50     $ 50            
Technion Research and Development Foundation Limited [Member] | Minimum [Member]                                        
Loss Contingencies [Line Items]                                        
Net sales royalty percenatge                   1.50%                    
Technion Research and Development Foundation Limited [Member] | Maximum [Member]                                        
Loss Contingencies [Line Items]                                        
Net sales royalty percenatge                   3.00%                    
CardioSert Ltd [Member] | Technology [Member]                                        
Loss Contingencies [Line Items]                                        
Payment to acquire intangible assets               $ 300                        
Number of common shares issued for acquisition | shares               6,738                        
Number of common shares issued for acquisition, value               $ 74                        
H.C. Wainwright & Co. LLC [Member]                                        
Loss Contingencies [Line Items]                                        
Warrant issued, descriptions         The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering.                              
H.C. Wainwright & Co. LLC [Member] | At-the-Market Offering Agreement [Member]                                        
Loss Contingencies [Line Items]                                        
Offering costs                                       $ 10,000
Stock issued during period, value, new issues       $ 8,000                                
Alliance Investment Management, Ltd. [Member]                                        
Loss Contingencies [Line Items]                                        
Litigation settlement             $ 468                          
2013 Through June 30, 2024 [Member] | Israeli Innovation Authority [Member]                                        
Loss Contingencies [Line Items]                                        
Revenue grants received                           $ 1,878            
[1] Net of issuance costs in the amount of approximately $328, of which approximately $52 had not been paid as of June 30, 2024. See also Note 4B.
[2] Net of issuance costs in the amount of approximately $333. See Note 4A.